Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

F Gaillard-Bigot1, X-Y Zendjidjian2, F Kheloufi1

  • 1Service de pharmacologie clinique et pharmacovigilance, CIC CPCET, assistance publique des hôpitaux de Marseille, Institut de neurosciences des systèmes, Inserm UMR 1106, université d'Aix-Marseille, France.

L'Encephale
|April 3, 2019
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Inclusive Search for Anomalous Single-Photon Production in MicroBooNE.

Physical review letters·2026
Same author

First Search for Dark Sector e^{+}e^{-} Explanations of the MiniBooNE Anomaly at MicroBooNE.

Physical review letters·2026
Same author

First Measurement of Charged-Current Muon-Neutrino-Induced K^{+} Production on Argon Using the MicroBooNE Detector.

Physical review letters·2026
Same author

Search for an Anomalous Production of Charged-Current ν_{e} Interactions without Visible Pions across Multiple Kinematic Observables in MicroBooNE.

Physical review letters·2025
Same author

First Measurement of ν_{e} and ν[over ¯]_{e} Charged-Current Single Charged-Pion Production Differential Cross Sections on Argon Using the MicroBooNE Detector.

Physical review letters·2025
Same author

First Double-Differential Cross Section Measurement of Neutral-Current π^{0} Production in Neutrino-Argon Scattering in the MicroBooNE Detector.

Physical review letters·2025
Same journal

Measuring antidepressant side effects in military personnel - Clinical validation of the French version of the UKU-SERS-Pat Scale: A comparative study of patient and clinician ratings.

L'Encephale·2026
Same journal

[Empowerment in addictology].

L'Encephale·2026
Same journal

Evaluation of the links between smoking and conspiracy mentality.

L'Encephale·2026
Same journal

Use of a relevance assessment tool in therapeutic residential care: A real world study.

L'Encephale·2026
Same journal

Prevalence and characteristics of domestic violence in a sample of adult psychiatric outpatients: A cross-sectional study.

L'Encephale·2026
Same journal

From representations to practice: how professionals describe supporting parents with psychiatric or somatic illness or disability.

L'Encephale·2026
See all related articles

Neuroscience advances enable early detection of schizophrenia prodromes, reconceptualizing it as an early-onset neurodevelopmental disorder. Future technologies promise improved diagnostics and symptomatic treatments for positive symptoms.

Area of Science:

  • Neuroscience
  • Psychiatry
  • Computational Biology

Background:

  • Schizophrenia treatment remains largely curative.
  • Neuroscience data over the past decade suggests reconceptualizing schizophrenia.
  • Early detection of at-risk stages or prodromes is now possible.

Purpose of the Study:

  • To explore the reconceptualization of schizophrenia based on recent neuroscience findings.
  • To highlight the potential of new technologies for early detection and treatment.
  • To outline future research directions in schizophrenia.

Main Methods:

  • Utilizing new neuroscience technologies like functional dynamic connectivity.
  • Identifying subtle clinical features indicative of early psychosis.
  • Leveraging advanced biomarkers and cognitive tools.
Keywords:
First-episodePharmacologiePharmacologyPremier épisodeSchizophreniaSchizophrénie

Related Experiment Videos

Main Results:

  • Schizophrenia is increasingly viewed as an early-onset neurodevelopmental disorder.
  • Polygenic risk factors are recognized.
  • Current treatments primarily address positive symptoms.

Conclusions:

  • New technologies offer potential for novel diagnostic and therapeutic strategies.
  • Future research should focus on pharmacological advancements.
  • Computational modeling approaches like quantitative system pharmacology hold promise.